01:00
AbstractAimsAccording to the 2019 European Society of Cardiology (ESC) guidelines on chronic coronary syndromes (CCS), adding a P2Y12 inhibitor or rivaroxaban to aspirin should be considered in high-risk patients. We estimated the proportion of patients eligible for treatment with the ESC (...)
01:00
National Institutes of Health and Massachusetts General Hospital Executive Committee on Research
01:00
Thrombotic and bleeding events underlie many cardiovascular diseases and complications of invasive and medical therapies. Thrombosis pervades all medical fields, from cancer and infections to lung, brain, blood, and metabolic disorders. The new EHJ team on thrombosis has worked actively during (...)